Dr. McGregor Discusses the Future of Treatment for RCC

Bradley McGregor, MD
Published: Monday, Sep 18, 2017



Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma (RCC).

Considering recent data with combinations such as axitinib (Inlyta) plus avelumab (Bavencio), and lenvatinib (Lenvima) plus pembrolizumab (Keytruda), McGregor believes that combinations in RCC will be moving toward the frontline setting.

Multiple trials are ongoing to determine what that combination will be.
 


Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma (RCC).

Considering recent data with combinations such as axitinib (Inlyta) plus avelumab (Bavencio), and lenvatinib (Lenvima) plus pembrolizumab (Keytruda), McGregor believes that combinations in RCC will be moving toward the frontline setting.

Multiple trials are ongoing to determine what that combination will be.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x